MEGAN TYNDALL: Open Payments
NPI 1861915779 · BERLIN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$516 in 21 payments from 10 companies in 2025. Trend: 2023 $140 · 2024 $247 · 2025 $516
Food & beverage: $516
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 5 | $83 |
| ABBVIE INC. | 3 | $61 |
| Merck Sharp & Dohme LLC | 2 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $40 |
| Novo Nordisk Inc | 2 | $39 |
| Aimmune Therapeutics, Inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $31 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
Products named: UPTRAVI, VOQUEZNA, GARDASIL 9, UBRELVY, GEMTESA, Veozah, VOWST, Wegovy.
Industry payments across MD — which companies pay providers there.
